Elite Pharmaceuticals, Inc. (ELTP) Gross margin 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) gross margin by fiscal year — reported gross profit divided by reported revenue.
50.4%FY2026 · since FY2017: 38.8% → 50.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 50.4% | +2.7 pp |
| FY2025 | 47.7% | +1.2 pp |
| FY2024 | 46.5% | -2.0 pp |
| FY2023 | 48.6% | +2.7 pp |
| FY2022 | 45.9% | -0.9 pp |
| FY2021 | 46.8% | +2.4 pp |
| FY2020 | 44.3% | +6.5 pp |
| FY2019 | 37.9% | -15.0 pp |
| FY2018 | 52.9% | +14.1 pp |
| FY2017 | 38.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Net marginELTP Gross profitELTP Operating incomeELTP Operating marginELTP Operating cash flowELTP Free cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →